zelicapavir
zelicapavir: developed by 1 company · 2 clinical trials tracked.
zelicapavir evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could zelicapavir → ENTA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | Phase 2 |
Clinical Trials (2)
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Primary endpoint: Time to complete resolution of clinical signs of RSV as measured by RESOLVE-P
Phase 1, Randomized, Double-Blind Four-Period Crossover, Thorough QT/QTc Study to Evaluate the Effects of EDP-938 on Cardiac Repolarization in Healthy Adults
Primary endpoint: Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of Zelicapavir
Frequently asked questions
Who is developing zelicapavir?
zelicapavir is being developed by ENANTA PHARMACEUTICALS INC.
How many clinical trials involve zelicapavir?
BioSniper tracks 2 clinical trials involving zelicapavir.